Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteochemonecrosis Provoked by Bisphosphonates

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2017-06-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of our study is to assess, after tooth extraction, the efficacity of PRF in the prevention of healing delay and of jawbone osteochemonecrosis induced by bisphosphonates

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Platelet Rich Fibrin Treatment for the Alveolar Ridge Preservation in Smokers

NCT06190860

Alveolar Process Atrophy Smoking, Cigarette Platelet-Rich Fibrin

RECRUITING NA

Influence of Platelet-Rich Fibrin on Post-extraction Alveolar Ridge Healing/Preservation as a Stand-alone or Adjunct to Particulate Graft

NCT02707536

Extraction Socket Healing Alveolar Ridge Preservation

COMPLETED NA

Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw

NCT06419010

Osteonecrosis of the Jaw

NOT_YET_RECRUITING NA

Alveolar Ridge Augmentation Following Tooth Extraction Using Bovine Xenograft With Platelet Rich Fibrin Membrane

NCT05791123

Bone Regeneration

COMPLETED NA

A 14 Weeks Longitudinal Study to Investigate the Effect of Leukocyte- Platelet Rich Fibrin Plug on the Quality of the Newly Formed Bone in Ridge Preservation Procedure Following a Tooth Extraction. It is a Clinical, Radiographic and Histomorphometric Study.

NCT03487718

Alveolar Ridge Preservation Tooth Extraction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Scientific Context Bisphosphonates (BP) work by slowing down bone remodelling. They are used in the management of different types of cancers and for the treatment of osteoporosis. Recent studies warned that this drug could produce adverse effects on jawbones .In December 2007, the AFSSAPS (French agency for the Sanitary Security of Health Products) alerted the health professionals about the risks of spontaneous or induced osteonecrosis following invasive odontological procedures on patients receiving BP. Prevalence of these osteonecrosis varies from 6% to 10% after surgical intervention. A healing delay estimated between 20 to 25% of cases frequently precedes the occurrence of osteochemonecrosis.

On the whole , the total rate of all complications amounts to 30%. We are extremely limited in terms of prevention or treatment of an OCN patient. We intend to study a biological autologous sediment obtained from a blood sample for its capacity to avoid these complications supervening. The collection of a coagulum called Platelet Rich Fibrin or PRF susceptible to provide the essential ingredients for the mucous membrane and the bone healing is obtained by centrifugation. This biomaterial rich in autologous fibrin is a concentrate of leukocytes, platelets and a number of factors favouring cicatrisation and immune response. Clinical applications are already well documented in orthopaedic, thoracic and cardiac surgeries and, also in dermatology. The use of PRF in dental surgery is more recent. Literature on this topic is very limited but these new techniques give rise to high hopes. Since February 2007,thanks to the classification as a medical treatment by the AFSSAPS, the PRF technique has been authorized.

Objectives To appraise after dental avulsion the PRF efficiency in preventing delay of cicatrisation and jawbone osteochemonecrosis induced by BP.

This efficiency will be assessed by a retroalveolar X-ray performed at each visit. The main criteria for evaluation is the discovery of cicatrisation delay at week 8 and/or osteochemonecrosis during the follow up.

Material and methods

Studied population: current or previous patients treated with BP and referred for a dental avulsion.

General experimental procedure: A prospective, longitudinal, multicentric, randomized open study. Patients will be randomized into two groups: dental avulsion only or dental avulsion and PRF. For both groups the initial management is surgical (bone curettage + PRF for the PRF group).The follow up is spread over one year with 10 visits. Each patient will undergo a clinical and photographic examination with a complete radiological check up(OPT),a standard biological blood test (blood count with haemogram (NFS) and a thorough calculation of the quantity of BP administered. The appearance of OCN or of any delay in cicatrisation will be documented by a histological biopsy, a bacteriological swab test and X-ray.

The requisite number of patients:

270 patients are required to validate the expected objectives in this study. Their recruitment will take place in 4 establishments: Metz-Thionville CHR (Regional Central Hospital) and three university teaching hospitals (CHU) Dijon, Nancy and Reims.

Total Duration of the study :

The estimated total duration will be 3 years: a 2 year recruitment with a 1 year follow-up.

Expected results and prospects To prove the interest of using PRF as a therapy able to prevent a delay in cicatrization or an OCN induced by BP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Jawbone Osteochemonecrosis Induced by Bisphosphonates

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bone curettage + PRF

Bone curettage and PRF insertion

Group Type EXPERIMENTAL

Bone curettage + PRF

Intervention Type PROCEDURE

Bone curettage and PRF insertion

Bone curettage alone

Bone curettage without PRF insertion

Group Type OTHER

Bone curettage alone

Intervention Type PROCEDURE

Bone curettage without PRF insertion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bone curettage + PRF

Bone curettage and PRF insertion

Intervention Type PROCEDURE

Bone curettage alone

Bone curettage without PRF insertion

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient major(male or female)
* Documented indication at the initial visit at day 0 (JO) for a maximum extraction of 3 teeth.
* Treatment with nitrogenous or non-nitrogenous BP by intravenous injection or oral administration whichever the reason for this drug prescription:

* on going BP treatment
* patient having received a previous treatment with bisphosphonates (irrespective of the duration and withdrawal date of this treatment)
* Patient having received the specific information letter regarding the study and having signed the clarified consent form.

Exclusion Criteria

* Patient having a maxillary or mandibulary OCN at Day 0(JO)
* Positive HIV serology at Day 0(for patients belonging to the PRF group)
* Previous history of maxillo-cervico-facial radiotherapy
* Patients with estimated survival expectancy shorter than one year
* Lack of social security cover
* Inability of the patient to respect the study follow-up
* Patient having reached his/her majority and under tutelage,trusteeship or protection of the court
* Patient whose diagnosis could not be revealed to him/her (especially when the patient or their family expressed this wish).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No